SG11201909115WA - Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof - Google Patents
Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereofInfo
- Publication number
- SG11201909115WA SG11201909115WA SG11201909115WA SG11201909115WA SG 11201909115W A SG11201909115W A SG 11201909115WA SG 11201909115W A SG11201909115W A SG 11201909115WA SG 11201909115W A SG11201909115W A SG 11201909115WA
- Authority
- SG
- Singapore
- Prior art keywords
- street
- international
- compounds
- gsk3
- cambridge
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 102000001267 GSK3 Human genes 0.000 title abstract 5
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101100176788 Dictyostelium discoideum gskA gene Proteins 0.000 title 1
- 101100149391 Drosophila melanogaster sgg gene Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- 201000006347 Intellectual Disability Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762481981P | 2017-04-05 | 2017-04-05 | |
| PCT/US2018/026339 WO2018187630A1 (fr) | 2017-04-05 | 2018-04-05 | Composés tricycliques en tant qu'inhibiteurs de glycogène synthase kinase 3 (gsk3) et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909115WA true SG11201909115WA (en) | 2019-10-30 |
Family
ID=63712671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909115W SG11201909115WA (en) | 2017-04-05 | 2018-04-05 | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11203601B2 (fr) |
| EP (1) | EP3606528B1 (fr) |
| JP (1) | JP7157075B2 (fr) |
| KR (1) | KR20190136063A (fr) |
| CN (1) | CN110958882B (fr) |
| AU (1) | AU2018249558A1 (fr) |
| BR (1) | BR112019020810A2 (fr) |
| CA (1) | CA3058198A1 (fr) |
| CO (1) | CO2019012324A2 (fr) |
| EA (1) | EA201992359A1 (fr) |
| IL (1) | IL269701A (fr) |
| MX (1) | MX2019011987A (fr) |
| SG (1) | SG11201909115WA (fr) |
| WO (1) | WO2018187630A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2909204T (pt) | 2012-10-12 | 2019-03-21 | Dana Farber Cancer Inst Inc | Inibidores de gsk3 e métodos de utilização dos mesmos |
| CN110041349B (zh) * | 2019-05-15 | 2021-06-01 | 湖南科技大学 | 一种含螺二氢嘧啶衍生物及其制备方法和应用 |
| WO2023246820A1 (fr) * | 2022-06-20 | 2023-12-28 | 上海优替济生生物医药有限公司 | Composé pour induire in vitro une cellule à mémoire de type cellule souche, et son application |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2722416A1 (de) | 1977-05-18 | 1978-11-30 | Thomae Gmbh Dr K | Neue thiazolo-pyridine |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| CA1283827C (fr) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Dispositif pour l'injection de formules liquides |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| JPH05157164A (ja) | 1991-12-03 | 1993-06-22 | Aisin Aw Co Ltd | 車両用自動変速機のサーボ油圧制御装置 |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| CN1058495C (zh) | 1993-04-08 | 2000-11-15 | 杜邦药品公司 | 在治疗识别障碍中用作神经递质释放增强剂的多环体系类化合物及其衍生物和含有它们的药物组合物及其用途 |
| WO1995024176A1 (fr) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Dispositif de remplissage d'ampoule |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5750528A (en) | 1995-02-01 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| TW526202B (en) | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
| WO2002062795A2 (fr) | 2001-02-02 | 2002-08-15 | Mitsubishi Pharma Corporation | Composes de dihydropyrazolopyridine et leur utilisation pharmaceutique |
| US6977262B2 (en) | 2001-02-02 | 2005-12-20 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| DE10121217A1 (de) * | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
| US7067507B2 (en) * | 2001-06-12 | 2006-06-27 | Pharmacia & Upjohn Company | Macrocycles useful in the treatment of Alzheimer's disease |
| DE602005018911D1 (de) | 2005-07-20 | 2010-03-04 | Aventis Pharma Sa | 1,4-Dihydropyridine-kondensierte Heterocyclen Verfahren zu deren Herstellung sowie Verwendung und Zusammensetzungen dergleichen |
| US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| US8778986B1 (en) | 2007-01-25 | 2014-07-15 | University Of South Florida | Treatment of glycogen synthase kinase-based disease |
| US20090181986A1 (en) | 2007-07-05 | 2009-07-16 | Matthew Abelman | Substituted heterocyclic compounds |
| US9265764B2 (en) | 2009-02-27 | 2016-02-23 | Massachusetts Institute Of Technology | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders |
| FR2945535B1 (fr) | 2009-05-18 | 2011-06-10 | Sanofi Aventis | Compose anticancereux et composition pharmaceutique le contenant |
| DE102011106990B3 (de) | 2011-07-08 | 2013-01-03 | Technische Universität Darmstadt | Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen |
| TW201406758A (zh) | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
| PT2909204T (pt) * | 2012-10-12 | 2019-03-21 | Dana Farber Cancer Inst Inc | Inibidores de gsk3 e métodos de utilização dos mesmos |
| US20160375006A1 (en) | 2012-10-12 | 2016-12-29 | The Broad Institute, Inc. | Uses of paralog-selective inhibitors of gsk3 kinases |
| WO2015087996A1 (fr) | 2013-12-13 | 2015-06-18 | 第一三共株式会社 | Dérivé d'imidazopyridine |
| KR101602559B1 (ko) | 2014-04-29 | 2016-03-10 | 경북대학교 산학협력단 | 2,5,6,7-사중치환 티아졸로[4,5-b]피리딘 유도체 및 이의 용도 |
| KR20170044144A (ko) | 2014-09-05 | 2017-04-24 | 메르크 파텐트 게엠베하 | 암 치료를 위한 인돌아민-2,3-디옥시게나제(ido) 길항제로서 시클로헥실-에틸 치환된 디아자- 및 트리아자-트리시클릭 화합물 |
-
2018
- 2018-04-05 CA CA3058198A patent/CA3058198A1/fr active Pending
- 2018-04-05 AU AU2018249558A patent/AU2018249558A1/en not_active Abandoned
- 2018-04-05 EA EA201992359A patent/EA201992359A1/ru unknown
- 2018-04-05 EP EP18781394.4A patent/EP3606528B1/fr active Active
- 2018-04-05 SG SG11201909115W patent/SG11201909115WA/en unknown
- 2018-04-05 US US16/603,112 patent/US11203601B2/en active Active
- 2018-04-05 JP JP2019554982A patent/JP7157075B2/ja active Active
- 2018-04-05 WO PCT/US2018/026339 patent/WO2018187630A1/fr unknown
- 2018-04-05 MX MX2019011987A patent/MX2019011987A/es unknown
- 2018-04-05 CN CN201880036981.1A patent/CN110958882B/zh active Active
- 2018-04-05 BR BR112019020810A patent/BR112019020810A2/pt not_active Application Discontinuation
- 2018-04-05 KR KR1020197032599A patent/KR20190136063A/ko unknown
-
2019
- 2019-09-26 IL IL26970119A patent/IL269701A/en unknown
- 2019-10-31 CO CONC2019/0012324A patent/CO2019012324A2/es unknown
-
2021
- 2021-10-22 US US17/507,922 patent/US20220112216A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190136063A (ko) | 2019-12-09 |
| WO2018187630A1 (fr) | 2018-10-11 |
| AU2018249558A1 (en) | 2019-11-07 |
| IL269701A (en) | 2019-11-28 |
| EP3606528A1 (fr) | 2020-02-12 |
| US20220112216A1 (en) | 2022-04-14 |
| EP3606528A4 (fr) | 2020-12-23 |
| BR112019020810A2 (pt) | 2020-04-28 |
| JP7157075B2 (ja) | 2022-10-19 |
| CN110958882A (zh) | 2020-04-03 |
| MX2019011987A (es) | 2020-07-14 |
| EA201992359A1 (ru) | 2020-03-12 |
| US20200109154A1 (en) | 2020-04-09 |
| WO2018187630A8 (fr) | 2019-01-03 |
| EP3606528B1 (fr) | 2023-10-18 |
| CO2019012324A2 (es) | 2020-05-15 |
| CA3058198A1 (fr) | 2018-10-11 |
| CN110958882B (zh) | 2023-08-29 |
| US11203601B2 (en) | 2021-12-21 |
| JP2020516616A (ja) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909710XA (en) | Indole ahr inhibitors and uses thereof | |
| SG11201903908PA (en) | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201906883SA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201909115WA (en) | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations |